These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
337 related articles for article (PubMed ID: 25406295)
21. Antimicrobial Activity of Ceftaroline Tested against Staphylococcus aureus from Surgical Skin and Skin Structure Infections in US Medical Centers. Sader HS; Farrell DJ; Flamm RK; Jones RN Surg Infect (Larchmt); 2016 Aug; 17(4):443-7. PubMed ID: 26990170 [TBL] [Abstract][Full Text] [Related]
22. Bacteremia due to Methicillin-Resistant Staphylococcus aureus: An Update on New Therapeutic Approaches. Holubar M; Meng L; Alegria W; Deresinski S Infect Dis Clin North Am; 2020 Dec; 34(4):849-861. PubMed ID: 33011050 [TBL] [Abstract][Full Text] [Related]
23. Method-specific performance of vancomycin MIC susceptibility tests in predicting mortality of patients with methicillin-resistant Staphylococcus aureus bacteraemia. Chen SY; Liao CH; Wang JL; Chiang WC; Lai MS; Chie WC; Chang SC; Hsueh PR J Antimicrob Chemother; 2014 Jan; 69(1):211-8. PubMed ID: 23997017 [TBL] [Abstract][Full Text] [Related]
33. In vitro activity of ceftobiprole on 440 Staphylococcus aureus strains isolated from bronchopulmonary infections. Hodille E; Delouere L; Bouveyron C; Meugnier H; Bes M; Tristan A; Laurent F; Vandenesch F; Lina G; Dumitrescu O Med Mal Infect; 2017 Mar; 47(2):152-157. PubMed ID: 27856079 [TBL] [Abstract][Full Text] [Related]
34. Phenotypic changes of methicillin-resistant Staphylococcus aureus during vancomycin therapy for persistent bacteraemia and related clinical outcome. Kim T; Kim ES; Park SY; Sung H; Kim MN; Kim SH; Lee SO; Choi SH; Jeong JY; Woo JH; Chong YP; Kim YS Eur J Clin Microbiol Infect Dis; 2017 Aug; 36(8):1473-1481. PubMed ID: 28337607 [TBL] [Abstract][Full Text] [Related]
35. Rates of killing of methicillin-resistant Staphylococcus aureus by ceftaroline, daptomycin, and telavancin compared to that of vancomycin. Marconescu P; Graviss EA; Musher DM Scand J Infect Dis; 2012 Aug; 44(8):620-2. PubMed ID: 22668202 [TBL] [Abstract][Full Text] [Related]
36. Methicillin-resistant Staphylococcus aureus in Stockholm, Sweden: Molecular epidemiology and antimicrobial susceptibilities to ceftaroline, linezolid, mupirocin and vancomycin in 2014. Fang H; Fröding I; Gian B; Hæggman S; Tollström UB; Ullberg M; Nord CE J Glob Antimicrob Resist; 2016 Jun; 5():31-5. PubMed ID: 27436463 [TBL] [Abstract][Full Text] [Related]
37. Ceftaroline fosamil: a cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Poon H; Chang MH; Fung HB Clin Ther; 2012 Apr; 34(4):743-65. PubMed ID: 22444785 [TBL] [Abstract][Full Text] [Related]
38. Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009-13). Sader HS; Farrell DJ; Flamm RK; Jones RN J Antimicrob Chemother; 2015 Jul; 70(7):2053-6. PubMed ID: 25814163 [TBL] [Abstract][Full Text] [Related]
39. Vancomycin MICs do not predict the outcome of methicillin-resistant Staphylococcus aureus bloodstream infections in correctly treated patients. Rojas L; Bunsow E; Muñoz P; Cercenado E; Rodríguez-Créixems M; Bouza E J Antimicrob Chemother; 2012 Jul; 67(7):1760-8. PubMed ID: 22556382 [TBL] [Abstract][Full Text] [Related]
40. In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program. Biedenbach DJ; Alm RA; Lahiri SD; Reiszner E; Hoban DJ; Sahm DF; Bouchillon SK; Ambler JE Antimicrob Agents Chemother; 2016 Jan; 60(1):343-7. PubMed ID: 26503659 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]